Karolinska Development AB (publ) (KDEV.ST)
SEK 0.85
(-0.47%)
SEK 0.85
(-0.47%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 2.8 Million SEK | 22.04% |
| 2022 | 2.3 Million SEK | 5.99% |
| 2021 | 2.17 Million SEK | -18.14% |
| 2020 | 2.65 Million SEK | -21.66% |
| 2019 | 3.38 Million SEK | 10.12% |
| 2018 | 3.07 Million SEK | 24.72% |
| 2017 | 2.46 Million SEK | -54.03% |
| 2016 | 5.36 Million SEK | 82.19% |
| 2015 | 2.94 Million SEK | 131.21% |
| 2014 | -9.42 Million SEK | 7.09% |
| 2013 | -10.14 Million SEK | 89.24% |
| 2012 | -94.26 Million SEK | -999.55% |
| 2011 | 10.47 Million SEK | -24.58% |
| 2010 | 13.89 Million SEK | -54.17% |
| 2009 | 30.32 Million SEK | 1205.77% |
| 2008 | 2.32 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 1.19 Million SEK | 220.11% |
| 2024 Q2 | 567 Thousand SEK | -52.51% |
| 2023 FY | 2.8 Million SEK | 22.04% |
| 2023 Q4 | 373 Thousand SEK | -9.47% |
| 2023 Q3 | 412 Thousand SEK | -20.92% |
| 2023 Q1 | 548 Thousand SEK | -2.49% |
| 2023 Q2 | 521 Thousand SEK | -4.93% |
| 2022 Q4 | 562 Thousand SEK | 6.64% |
| 2022 Q2 | 621 Thousand SEK | 5.25% |
| 2022 Q1 | 590 Thousand SEK | 25.8% |
| 2022 FY | 2.3 Million SEK | 5.99% |
| 2022 Q3 | 527 Thousand SEK | -15.14% |
| 2021 Q3 | 497 Thousand SEK | -13.57% |
| 2021 Q2 | 575 Thousand SEK | -8.59% |
| 2021 Q4 | 469 Thousand SEK | -5.63% |
| 2021 FY | 2.17 Million SEK | -18.14% |
| 2021 Q1 | 629 Thousand SEK | 19.13% |
| 2020 Q1 | 1.1 Million SEK | 51.65% |
| 2020 FY | 2.65 Million SEK | -21.66% |
| 2020 Q3 | 430 Thousand SEK | -26.99% |
| 2020 Q4 | 528 Thousand SEK | 22.79% |
| 2020 Q2 | 589 Thousand SEK | -46.65% |
| 2019 Q2 | 1.03 Million SEK | 14.93% |
| 2019 Q4 | 728 Thousand SEK | 2.1% |
| 2019 FY | 3.38 Million SEK | 10.12% |
| 2019 Q3 | 713 Thousand SEK | -31.38% |
| 2019 Q1 | 904 Thousand SEK | 5.98% |
| 2018 Q3 | 728 Thousand SEK | -3.96% |
| 2018 Q1 | 734 Thousand SEK | -2.26% |
| 2018 FY | 3.07 Million SEK | 24.72% |
| 2018 Q4 | 853 Thousand SEK | 17.17% |
| 2018 Q2 | 758 Thousand SEK | 3.27% |
| 2017 Q1 | 616 Thousand SEK | -83.4% |
| 2017 Q4 | 751 Thousand SEK | 39.85% |
| 2017 Q2 | 560 Thousand SEK | -9.09% |
| 2017 FY | 2.46 Million SEK | -54.03% |
| 2017 Q3 | 537 Thousand SEK | -4.11% |
| 2016 Q1 | 608 Thousand SEK | 19.69% |
| 2016 FY | 5.36 Million SEK | 82.19% |
| 2016 Q3 | 435 Thousand SEK | -28.34% |
| 2016 Q4 | 3.71 Million SEK | 752.87% |
| 2016 Q2 | 607 Thousand SEK | -0.16% |
| 2015 Q3 | 324 Thousand SEK | -71.02% |
| 2015 FY | 2.94 Million SEK | 131.21% |
| 2015 Q1 | -3.5 Million SEK | 72.76% |
| 2015 Q2 | 1.11 Million SEK | 131.88% |
| 2015 Q4 | 508 Thousand SEK | 56.79% |
| 2014 Q2 | 1.1 Million SEK | -11.37% |
| 2014 FY | -9.42 Million SEK | 7.09% |
| 2014 Q4 | -12.87 Million SEK | -1276.87% |
| 2014 Q3 | 1.09 Million SEK | -1.17% |
| 2014 Q1 | 1.24 Million SEK | 107.15% |
| 2013 Q4 | -17.48 Million SEK | -733.56% |
| 2013 Q3 | 2.75 Million SEK | 161.64% |
| 2013 Q2 | -4.47 Million SEK | 13.81% |
| 2013 FY | -10.14 Million SEK | 89.24% |
| 2013 Q1 | -5.19 Million SEK | 81.2% |
| 2012 Q2 | 3.07 Million SEK | 24.2% |
| 2012 Q1 | 2.47 Million SEK | -26.43% |
| 2012 Q4 | -27.62 Million SEK | -43.4% |
| 2012 Q3 | -19.26 Million SEK | -726.58% |
| 2012 FY | -94.26 Million SEK | -999.55% |
| 2011 Q1 | 2.9 Million SEK | 0.0% |
| 2011 Q4 | 3.36 Million SEK | 73.76% |
| 2011 FY | 10.47 Million SEK | -24.58% |
| 2011 Q2 | 2.27 Million SEK | -21.48% |
| 2011 Q3 | 1.93 Million SEK | -15.01% |
| 2010 FY | 13.89 Million SEK | -54.17% |
| 2010 Q3 | - SEK | 0.0% |
| 2009 FY | 30.32 Million SEK | 1205.77% |
| 2008 FY | 2.32 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 99.752% |
| AcouSort AB (publ) | 8.38 Million SEK | 66.54% |
| Active Biotech AB (publ) | -1.67 Million SEK | 267.582% |
| Alzinova AB (publ) | 19.87 Million SEK | 85.876% |
| Amniotics AB (publ) | -1.93 Million SEK | 245.44% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | 763.593% |
| BioArctic AB (publ) | 346.31 Million SEK | 99.189% |
| Camurus AB (publ) | 1.58 Billion SEK | 99.822% |
| Cantargia AB (publ) | -3.45 Million SEK | 181.339% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | -69.3% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 74.978% |
| Genovis AB (publ.) | 54 Million SEK | 94.802% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | 18813.333% |
| Mendus AB (publ) | 28.48 Million SEK | 90.146% |
| Kancera AB (publ) | -1.96 Million SEK | 242.85% |
| LIDDS AB (publ) | -12.92 Million SEK | 121.723% |
| Lipum AB (publ) | 53 Thousand SEK | -5196.226% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 154.856% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 71.826% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | -43.74 Million SEK | 106.416% |
| OncoZenge AB (publ) | 3000.00 SEK | -93466.667% |
| Saniona AB (publ) | 11.78 Million SEK | 76.173% |
| Simris Alg AB (publ) | 2 Million SEK | -39.86% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | 182.052% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 92.068% |
| Xintela AB (publ) | 78 Thousand SEK | -3498.718% |
| Ziccum AB (publ) | -23.28 Million SEK | 112.054% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 108.156% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 130.531% |
| CombiGene AB (publ) | -21.29 Million SEK | 113.184% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | 178.408% |
| Intervacc AB (publ) | -13.79 Million SEK | 120.349% |
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 101.747% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 93.283% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | -29.295% |
| Corline Biomedical AB | 28.38 Million SEK | 90.109% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 102.287% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 89.534% |
| Aptahem AB (publ) | 2.63 Million SEK | -6.704% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -3545.455% |
| Fluicell AB (publ) | 1.73 Million SEK | -61.507% |
| Biovica International AB (publ) | 6.87 Million SEK | 59.183% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 112.056% |
| Abliva AB (publ) | -35.66 Million SEK | 107.871% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 101.911% |
| 2cureX AB (publ) | -37.48 Million SEK | 107.488% |
| I-Tech AB | 27.56 Million SEK | 89.817% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 96.044% |
| Cyxone AB (publ) | 2.61 Million SEK | -7.507% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | 17.514% |
| Biosergen AB | -456 Thousand SEK | 715.57% |
| Nanologica AB (publ) | -76 Thousand SEK | 3793.421% |
| SynAct Pharma AB | -778 Thousand SEK | 460.797% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | 1554.404% |
| BioInvent International AB (publ) | 71.46 Million SEK | 96.072% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 92.267% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -91.863% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | 367.588% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | 10.405% |